Skip to main content

Prelude Therapeutics Inc

PRLD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001678660

No open-market purchases or sales by Prelude Therapeutics Inc insiders were filed in the last 90 days; 75 institutions reported holding it in 13F filings for Q2 2026, worth $264.3M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Prelude Therapeutics Inc changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of PRLD: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders7062−8
Shares35.8M32.2M−3.58M (−10.0%)
Value$74.0M$41.0M−$33.0M (−44.6%)

New holders (8)

Institutions that held Prelude Therapeutics Inc at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to PRLD in Q4 2024
InstitutionSharesValue% of portfolio
Boxer Capital Management, LLC1,708,187$2.18M0.19%
Susquehanna International Group, LLP72,799$92.8K0.00%
BNP Paribas Arbitrage, SA20,572$26.2K0.00%
AQR Capital Management LLC12,493$15.9K0.00%
JustInvest LLC11,925$15.2K0.00%
Militia Capital Partners, LP4,300$5.48K0.00%
SBI Securities Co., Ltd.2,741$3.50K0.00%
Nisa Investment Advisors, LLC508$6480.00%

Sold out (16)

Institutions that held Prelude Therapeutics Inc at the end of Q3 2024 and filed for Q4 2024 without it.